Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Profit After Tax (2016 - 2025)

Guided Therapeutics' Profit After Tax history spans 15 years, with the latest figure at -$742000.0 for Q3 2025.

  • For Q3 2025, Profit After Tax fell 13.46% year-over-year to -$742000.0; the TTM value through Sep 2025 reached -$2.2 million, down 2.53%, while the annual FY2024 figure was -$2.4 million, 30.73% up from the prior year.
  • Profit After Tax for Q3 2025 was -$742000.0 at Guided Therapeutics, up from -$811000.0 in the prior quarter.
  • Across five years, Profit After Tax topped out at $68000.0 in Q3 2021 and bottomed at -$1.8 million in Q4 2022.
  • The 5-year median for Profit After Tax is -$677000.0 (2023), against an average of -$730022.5.
  • The largest annual shift saw Profit After Tax plummeted 1720.59% in 2022 before it skyrocketed 99.95% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$444000.0 in 2021, then crashed by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then plummeted by 68.91% to -$652000.0 in 2024, then decreased by 13.8% to -$742000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Profit After Tax are -$742000.0 (Q3 2025), -$811000.0 (Q2 2025), and -$427.0 (Q1 2025).